Nextech VII Oncology SCSp is a venture capital fund based in Senningerberg, Luxembourg. According to its most recent Form D, filed Apr 13, 2023, it has sold $247,062,500 of interests to 95 investors since its first sale in Nov 2021. The filing does not set a minimum investment. It relies on the Section 3(c)(7) exclusion, so investors generally must be qualified purchasers. The offering uses Rule 506(b), which does not permit general solicitation. Related persons named in the filing include Rocco Sgobbo; Costas Constantinides; Nextech VII GP S.a r.l.
- Total raised
- $247,062,500Cumulative sales reported on Form D
- Investors
- 95
- First sale
- Nov 24, 2021
- Minimum investment
- None set
- Who can invest
- Qualified purchasersSection 3(c)(7): generally $5M+ in investments
- Offering exemption
- Rule 506(b)No general advertising
- Key people and entities
- Rocco Sgobbo; Costas Constantinides; Nextech VII GP S.a r.l
- Latest Form D
- Apr 13, 2023
From SEC filings, not verified. This page republishes the fund's Form D as filed. It is not an offer, solicitation or recommendation, and AltMountain has not reviewed the fund. “Raised” is cumulative sales, not current assets or performance. Returns are not part of SEC filings. Private funds are speculative, illiquid and generally limited to accredited investors or qualified purchasers. Full disclosures · Request a correction
Raise history
| Filed | Filing | Total raised | Investors | Source |
|---|---|---|---|---|
| Apr 13, 2023 | Form D/A (amendment) | $247,062,500 | 95 | SEC.gov ↗ |
| Nov 15, 2022 | Form D/A (amendment) | $235,062,500 | 38 | SEC.gov ↗ |
| Nov 16, 2021 | Form D | $0 | 0 | SEC.gov ↗ |
3 Form D filings in the SEC's electronic records (2008 onward), the earliest on Nov 16, 2021. Each filing reports the cumulative amount sold and the number of investors to that date, as the fund filed it. Not verified, and not the fund's current assets. Source: U.S. Securities and Exchange Commission, Form D data sets.
Foundations that report holding this fund
| Foundation | State | Value reported | Basis | Tax year ended |
|---|---|---|---|---|
| Diana Davis Spencer Foundation Inc | MD | $4,867,104 | fair market value | Dec 31, 2024 |
| The Muse Family Foundation | TX | $108,788 | fair market value | Dec 31, 2024 |
2 private foundations listed this fund by name among the investments on their IRS Form 990-PF. The value is the year-end figure the foundation reported, exactly as filed (fair market value where given, otherwise book value); holdings may have changed since, and other investors in the fund are not listed. Matched by the fund's full name; not verified by AltMountain or by the fund. Source: Internal Revenue Service, Form 990 series e-file data.
Questions about Nextech VII Oncology SCSp
What is the minimum investment for Nextech VII Oncology SCSp?
Nextech VII Oncology SCSp's latest Form D, filed Apr 13, 2023, does not set a minimum investment. Managers can still require one in the offering documents.
Who can invest in Nextech VII Oncology SCSp?
Nextech VII Oncology SCSp is generally open only to qualified purchasers (generally individuals with at least $5 million in investments), because it relies on Section 3(c)(7). It uses Rule 506(b), which does not allow general advertising.
How much has Nextech VII Oncology SCSp raised?
Nextech VII Oncology SCSp reports $247,062,500 sold from 95 investors on its Form D filed Apr 13, 2023. This is cumulative sales since the offering began, not current assets or performance.
Where is Nextech VII Oncology SCSp based?
Nextech VII Oncology SCSp is based in Senningerberg, Luxembourg.
When did Nextech VII Oncology SCSp launch?
Nextech VII Oncology SCSp reports its first sale in Nov 2021.
Size compared with every venture capital fund
Raised more than 100% of the 24 venture capital funds based in Luxembourg, and more than 99% of all 14,876 that report sales.